Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes

L. Tamási, Maria Szilasi, Gabriella Gálffy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler®, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO). Methods: Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler® and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed. Results: A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler® use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler® from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler® as ‘very good’ and > 90.0% of physicians described the Bufomix Easyhaler® as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively. Conclusion: Twelve weeks’ treatment with the Bufomix Easyhaler® resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler® was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler® in the treatment of adult outpatients with obstructive airway disease. Funding: Orion Corp., Orion Pharma.

Original languageEnglish
Pages (from-to)1140-1152
Number of pages13
JournalAdvances in Therapy
Volume35
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Budesonide
Nebulizers and Vaporizers
Asthma
Chronic Obstructive Pulmonary Disease
Quality of Life
Physicians
Respiratory Therapy
Hungary
Spirometry
Therapeutics
Formoterol Fumarate
Patient Reported Outcome Measures
Patient Satisfaction
Dyspnea
Lung Diseases
Biomedical Research
Teaching
Outpatients
Equipment and Supplies

Keywords

  • ACO
  • Asthma
  • Budesonide/formoterol Easyhaler
  • COPD
  • Effectiveness
  • Real-world study
  • Respiratory/pulmonary

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{bf0876656f69498099c56420a0e0bfee,
title = "Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler{\circledR} for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes",
abstract = "Introduction: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler{\circledR}, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO). Methods: Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler{\circledR} and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed. Results: A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4{\%}) were newly diagnosed inhaler-na{\"i}ve patients and 1043 (69.6{\%}) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler{\circledR} use. Improvements were observed in both inhaler-na{\"i}ve patients and those who switched to a Bufomix Easyhaler{\circledR} from other devices. After switching, 72.4{\%} of patients regarded the Bufomix Easyhaler{\circledR} as ‘very good’ and > 90.0{\%} of physicians described the Bufomix Easyhaler{\circledR} as easy to teach; 73.8{\%} and 98.9{\%} of patients learned the technique within 5 and 10 min of teaching, respectively. Conclusion: Twelve weeks’ treatment with the Bufomix Easyhaler{\circledR} resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler{\circledR} was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler{\circledR} in the treatment of adult outpatients with obstructive airway disease. Funding: Orion Corp., Orion Pharma.",
keywords = "ACO, Asthma, Budesonide/formoterol Easyhaler, COPD, Effectiveness, Real-world study, Respiratory/pulmonary",
author = "L. Tam{\'a}si and Maria Szilasi and Gabriella G{\'a}lffy",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s12325-018-0753-6",
language = "English",
volume = "35",
pages = "1140--1152",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease

T2 - a Real-World Study of Patient-Reported Outcomes

AU - Tamási, L.

AU - Szilasi, Maria

AU - Gálffy, Gabriella

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Introduction: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler®, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO). Methods: Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler® and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed. Results: A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler® use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler® from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler® as ‘very good’ and > 90.0% of physicians described the Bufomix Easyhaler® as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively. Conclusion: Twelve weeks’ treatment with the Bufomix Easyhaler® resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler® was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler® in the treatment of adult outpatients with obstructive airway disease. Funding: Orion Corp., Orion Pharma.

AB - Introduction: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler®, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO). Methods: Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler® and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed. Results: A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler® use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler® from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler® as ‘very good’ and > 90.0% of physicians described the Bufomix Easyhaler® as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively. Conclusion: Twelve weeks’ treatment with the Bufomix Easyhaler® resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler® was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler® in the treatment of adult outpatients with obstructive airway disease. Funding: Orion Corp., Orion Pharma.

KW - ACO

KW - Asthma

KW - Budesonide/formoterol Easyhaler

KW - COPD

KW - Effectiveness

KW - Real-world study

KW - Respiratory/pulmonary

UR - http://www.scopus.com/inward/record.url?scp=85051442759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051442759&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0753-6

DO - 10.1007/s12325-018-0753-6

M3 - Article

AN - SCOPUS:85051442759

VL - 35

SP - 1140

EP - 1152

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 8

ER -